Michael Burshtine

OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ.

PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY.

Part of PricewaterhouseCoopers International Ltd., Kesselman & Kesselman is an Israeli company that provides accounting services. The company is based in Tel Aviv, Israel.

Flight Medical Innovations Ltd. engages in the development, manufacture, and marketing of versatile ventilators. Its products include Flight 60 and Vento2ux. The company was founded in 1963 and is headquartered Petach-Tikva, Israel.

Recoly NV operates as a biotech company focusing on the discovery, development and commercialization of drug enhancing technologies that are used to create bio-better drugs. Its pipeline includes multiple products; all based on their proprietary technologies, in different development stages from marketing authorization filing through pivotal to pre-clinical studies. The company was founded by Robert Taub in 1992 and is headquartered in Brussels, Belgium.

Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel.